Search over 3,000 reports

    Actinic Keratosis- Epidemiology Forecast to 2023

    Actinic Keratosis- Epidemiology Forecast to 2023
    Date: Dec, 2017
    Type: Pharmaceutical Industry Report
    Pages: 40
    Geography: Global
    Delivery Timeline: 48 hrs
    SKU: DIEI0014
    DelveInsight's "Actinic Keratosis - Epidemiology Insights, 2023" report provides an overview of the disease of the Actinic Keratosis for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Actinic Keratosis from 2013-2023.
    Actinic Keratosis (AK) commonly known as a solar keratosis is a precancerous crusty lesion caused by damage from exposure to ultraviolet (UV) radiation. It is considered a pre-cancer condition if left untreated could develop into a skin cancer, most often squamous cell carcinoma (SCC). AKs appear on areas which are most commonly exposed to sun such as the face, scalp, shoulders, neck, the back of the hands and forearms, etc.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

    Scope
    The report provides historical as well as forecasted epidemiology of Actinic Keratosis in the 7MM.
    Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
    1. Report Introduction
    2. Snapshot of Total Prevalent or Incident cases by 7 MM
    3. Executive Summary
    • Key Findings
    4. Actinic Keratosis Overview
    • Actinic Keratosis Definition
    • Pathophysiology
    • Symptoms
    • Etiology
    5. Risk Factors Associated with Actinic Keratosis
    6. Disease Burden & Unmet Need in the Market
    7. Epidemiology and Patient Populations
    • Key Findings
    • Key Sources used and Forecast Methodology
    • Prevalent Cases and Incident Cases-2015-2025
    • Prevalent & Incident Cases by Category-2015-2025
    • Age-Specific Prevalent/ Incident Cases of Actinic Keratosis
    • Sex-Specific Prevalent/Incident Cases of Actinic Keratosis
    • Disease Type Specific Prevalent/Incident Cases of Actinic Keratosis
    8.Prevalent & Incident Cases by 7 MM-2015-2025
    • Actinic Keratosis Epidemiology of United States-2025
    • Actinic Keratosis Epidemiology of United Kingdom-2025
    • Actinic Keratosis Epidemiology of Germany-2025
    • Actinic Keratosis Epidemiology of France-2025
    • Actinic Keratosis Epidemiology of Spain-2025
    • Actinic Keratosis Epidemiology of Italy-2025
    • Actinic Keratosis Epidemiology of Japan-2025
    9. Key Takeaways
    10. Appendix
    11.Report Methodology
    12. Consulting Services
    13. Disclaimer
    14. About Us
    Table 1: Prevalent and Treatable Population of Actinic Keratosis in United States (2013-2023)
    Table 2: Prevalent and Treatable Population of Actinic Keratosis in Germany (2013-2023)
    Table 3: Prevalent and Treatable Population of Actinic Keratosis in France (2013-2023)
    Table 4: Prevalent and Treatable Population of Actinic Keratosis in United Kingdom (2013-2023)
    Table 5: Prevalent and Treatable Population of Actinic Keratosis in Italy (2013-2023)
    Table 6: Prevalent and Treatable Population of Actinic Keratosis in Spain (2013-2023)
    Table 7: Prevalent and Treatable Population of Actinic Keratosis in Japan(2013-2023)
    Figure 1: Prevalent and Treatable Population of Actinic Keratosis in United States (2013-2023)
    Figure 2: Prevalent and Treatable Population of Actinic Keratosis in Germany (2013-2023)
    Figure 3: Prevalent and Treatable Population of Actinic Keratosis in Italy (2013-2023)
    Figure 4: Prevalent and Treatable Population of Actinic Keratosis in Spain (2013-2023)
    Figure 5: Prevalent and Treatable Population of Actinic Keratosis in France (2013-2023)
    Figure 6: Prevalent and Treatable Population of Actinic Keratosis in United Kingdom (2013-2023)
    Figure 7: Prevalent and Treatable Population of Actinic Keratosis in Japan (2013-2023)
    Figure 8: IngenolDisoxate, Clinical Trials by Zone, 2017
    Figure 9:Clinical Trials by Recruitment status, 2017
    Figure 10: Number of Products under development by Companies, 2017
    Figure 11: Clinical Stage Products, 2017
    Figure 12: Pre-Clinical Stage Products, 2017
    Figure 13: Assessment by Monotherapy Products, 2017
    Figure 14: Assessment by Combination Products, 2017
    Figure 15: Assessment by Route Of Administration, 2017
    Figure 16: Assessment by Stage and Route Of Administration, 2017
    Figure 17: Assessment by Molecule Type, 2017
    Figure 18: Assessment by Stage and Molecule Type, 2017
    Figure 19: Assessment by Stage of development and Domain, 2017
    Figure 20: Assessment by Stage of development and Domain, 2017
    Figure 21: Total Market size of Actinic Keratosis in USD Million (2013-2023)
    Figure 22: United States Market Size of Actinic Keratosis in USD, Million (2013-2023)
    Figure 23: Germany Market Size of Actinic Keratosis in USD, Million (2013-2023)
    Figure 24: Italy Market Size of Actinic Keratosis in USD, Million (2013-2023)
    Figure 25: Spain Market Size of Actinic Keratosis in USD, Million (2013-2023)
    Figure 26: France Market Size of Actinic Keratosis in USD, Million (2013-2023)
    Figure 27: United Kingdom Market Size of Actinic Keratosis in USD, Million (2013-2023)
    Figure 28:Japan Market Size of Actinic Keratosis in USD, Million (2013-2023)


    Actinic Keratosis Disease Overview

    Actinic Keratosis Prevalence

    Actinic Keratosis Incidence

    Actinic Keratosis Risk Factors

    Actinic Keratosis Epidemiology

    Actinic Keratosis Patient Populations

    Actinic Keratosis Diagnosed Patients

    Actinic Keratosis Forecast

    Actinic Keratosis Epidemiology Forecast

    Actinic Keratosis Treated patients/population

    • Single User License
      (20% Off)
      $2,750.00
    • Site License
      (30% Off)
      $5,500.00
    • Global License
      (40% Off)
      $8,250.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap